The medical outlay costs associated with healthcare filed are expensive due to the high costs of the existing products in the market which are mostly imported from European/American markets. The constantly growing demands for robust 3D platforms to mimic pathological conditions point towards a need for sustainable and affordable approaches. For addressing these problem definitions and motivations from the ‘Atmanirbhar Bharat” and ‘Innovation India’ missions (as conceived by the Government of India), I aim to develop ‘new generation smart 3D bioprinted products for sustainable and affordable healthcare and high throughput drug screening platforms’ using inexpensive and patient specific smart biomaterials for improving the current clinical scenario.